Abstract:Cardiac amyloidosis (CA) is characterized by progressive pathological deposition of amyloid fibrils in the myocardial interstitium, resulting ultimately in restrictive cardiomyopathy. The amyloid fibrils accumulating in the heart are most commonly misfolded immunoglobulin light chains (in case of AL amyloidosis) or transthyretin (ATTR), the latter being either in wild-type or variant conformation.Overall, heart involvement is one of the strongest predictors of poor prognosis, with a median survival after diagnosis that ranges from less than 12 months for AL amyloidosis to 3–5 years for ATTR amyloidosis.[1] Therefore, early detection and phenotyping of CA are crucial to stratify prognosis and guide treatment.In the last decade, cardiac magnetic resonance (CMR) and bone scintigraphy have led to a major breakthrough in the accuracy of diagnosis of CA.CMR allows detailed evaluation of structural and functional changes related to each stage of CA, from asymptomatic occasional finding to advanced heart failure.The pathological deposition of amyloid fibrils results in biventricular wall thickening and preserved ejection fraction (EF), at least until late. However, the systolic function of the heart is abnormal. Since the early stages of the disease, global longitudinal strain is characteristically reduced for both the left ventricle and right ventricle, sparing the apical segments, with a so-called "apical sparing" pattern.[2] The indexed stroke volume may be reduced. The decrease in EF is commonly seen in the advanced stage of the disease and is invariably associated with heart failure and poor survival rate, especially in case of AL amyloidosis.The infiltration of amyloid proteins can also involve the atria, the interatrial septum, and atrioventricular valves causing hypertrophy ([Fig. 1A]). Recently, a high prevalence of ATTR in patients with severe calcific aortic stenosis has been reported and a pathophysiological association has been hypothesized.[3] CMR is able to detect all the previously mentioned structural abnormalities and provides a comprehensive evaluation of the systolic function of the heart. However, diastolic function is not formally assessed.The key advantage of CMR in CA is its unique ability to give information about the tissue composition by "myocardial tissue characterization," both with and without administration of gadolinium.After the administration of contrast, in case of massive interstitial expansion due to amyloid, it could be difficult or even impossible to null the myocardium according to the late gadolinium enhancement (LGE) technique. This is an almost pathognomonic sign for CA. With a phase sensitive inversion recovery approach, three patterns of LGE could be present: none, subendocardial, or transmural. The subendocardial distribution is typically "tram-line," involving both the ventricles, especially the basal segments, not following coronary artery distribution territories. Along with the progression of amyloid deposition, a transmural pattern of LGE can be seen. This is associated with a fivefold increase in mortality compared with patients with CA without LGE.[4] In the most advanced stages, pan-myocardial LGE has been described ([Fig. 1B]).Due to the high prevalence of severe chronic kidney disease in patients with systemic amyloidosis, a great interest has grown in native T1-mapping, which allows tissue characterization without administration of contrast.[5] Along with the expansion of the interstitial space due to amyloid accumulation, native T1-mapping and extracellular volume (ECV)-mapping are significantly elevated in patients with CA ([Fig. 1C]). This sign is very specific and correlates with prognosis. Moreover, elevated T1-mapping and ECV-mapping could be found also in the absence or ill-defined LGE, thus acting as a potential early marker of disease.In conclusion, CMR is fundamental for the diagnosis of CA. Its specificity and accuracy paid the way to the development of algorithms for a definitive diagnosis of CA without the need of biopsy. However, despite scores based on difference in the pattern of LGE have been proposed (QALE [quality adjusted life expectancy] score reference), it is still not possible to characterize the type of amyloid deposition based on CMR findings.Therefore, clinical suspicion and expertise are needed to integrate the information derived from imaging into the clinical setting for the care of patients with CA.Article published online:02 February 2022© 2022. Official Publication of The Simulation Society (TSS), accredited by International Society of Cardiovascular Ultrasound (ISCU). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, -Abstract Truncated-

99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis

Usefulness of scintigraphy with [99mTc]Tc-DPD for the detection of transthyretin cardiac amyloidosis. Reference centre experience in an endemic area

A Risk Score to Diagnose Cardiac Involvement and Provide Prognosis Information in Patients at Risk of Cardiac Light-Chain Amyloidosis

Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores

Single-center analysis of cardiac amyloidosis using 99mTc-HMDP imaging for diagnosis and evaluation after tafamidis treatment

Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function

False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: Case report

Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis

DPD quantification correlates with ECV and disease severity in patients with ATTR-CM

Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis

An optimized imaging protocol for [99mTc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis

Mitral Annular Calcification as a Potential False-Positive for Cardiac Amyloidosis in 99mTc-DPD Scintigraphy Accurately Identified by SPECT/CT

DPD Quantification Correlates With Extracellular Volume and Disease Severity in Wild-Type Transthyretin Cardiac Amyloidosis

Negative Methylene Diphosphonate Scintigraphy in Biopsy-Confirmed Hereditary Transthyretin Ala117Ser Cardiac Amyloidosis: a Case Report

Consensus to 99m Technetium?Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin?related Cardiac Amyloidosis

Myocardial Scintigraphy in Diagnosing Cardiac Transthyretin Amyloidosis

Evaluation of ATTR-cardiac amyloidosis employing Tc-99m pyrophosphate scintigraphy using planar, SPECT and gated SPECT imaging on dedicated cardiac CZT camera

The short and long-term characteristics and outcomes of patients with grade 1 myocardial uptake on cardiac scintigraphy

Trends in diagnosis of cardiac transthyretin amyloidosis: 3-year analysis of scintigraphic studies: Prevalence of myocardial uptake and its predictor factors

Role of Cardiac Magnetic Resonance in the Diagnosis of Cardiac Amyloidosis

99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy